382 related articles for article (PubMed ID: 26906637)
21. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
22. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
23. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
24. Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties.
Palluotto F; Sosic A; Pinato O; Zoidis G; Catto M; Sissi C; Gatto B; Carotti A
Eur J Med Chem; 2016 Nov; 123():704-717. PubMed ID: 27521587
[TBL] [Abstract][Full Text] [Related]
25. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity.
Riou JF; Grondard L; Naudin A; Bailly C
Biochem Pharmacol; 1995 Jul; 50(3):424-8. PubMed ID: 7646545
[TBL] [Abstract][Full Text] [Related]
26. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
[TBL] [Abstract][Full Text] [Related]
27. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
28. Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Žegura B; Filipič M; Solmajer T; Perdih A
ChemMedChem; 2015 Feb; 10(2):345-59. PubMed ID: 25522133
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Human Topoisomerase II by N,N,N-Trimethylethanammonium Iodide Alkylcarbazole Derivatives.
Saturnino C; Caruso A; Iacopetta D; Rosano C; Ceramella J; Muià N; Mariconda A; Bonomo MG; Ponassi M; Rosace G; Sinicropi MS; Longo P
ChemMedChem; 2018 Dec; 13(24):2635-2643. PubMed ID: 30347518
[TBL] [Abstract][Full Text] [Related]
30. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
Fossé P; René B; Charra M; Paoletti C; Saucier JM
Mol Pharmacol; 1992 Oct; 42(4):590-5. PubMed ID: 1331751
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
34. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives.
Monnot M; Mauffret O; Simon V; Lescot E; Psaume B; Saucier JM; Charra M; Belehradek J; Fermandjian S
J Biol Chem; 1991 Jan; 266(3):1820-9. PubMed ID: 1846365
[TBL] [Abstract][Full Text] [Related]
35. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
[TBL] [Abstract][Full Text] [Related]
36. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of functionalized ellipticinium and ellipticine derivatives via electrophilic cyclization.
Chaitanya TK; Nagarajan R
Org Biomol Chem; 2011 Jun; 9(12):4662-70. PubMed ID: 21509384
[TBL] [Abstract][Full Text] [Related]
38. Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate.
Bender RP; Lehmler HJ; Robertson LW; Ludewig G; Osheroff N
Biochemistry; 2006 Aug; 45(33):10140-52. PubMed ID: 16906772
[TBL] [Abstract][Full Text] [Related]
39. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.
Ketron AC; Denny WA; Graves DE; Osheroff N
Biochemistry; 2012 Feb; 51(8):1730-9. PubMed ID: 22304499
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
